Metabolomics in Nephrotoxicity

Advances in Clinical Chemistry

Volumn 65, Issue , 2014, Pages 69-89

  Zhao, Ying Yong ^a   Lin, Rui Chao ^b  

^a NORTHWEST UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Kidney injury; Mass spectrometry; Metabolomics; Metabonomics; Nephrotoxicity; Nuclear magnetic resonance spectroscopy; Renal toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MELAMINE; TRIAZINE DERIVATIVE;

ANIMAL; ARTICLE; DRUG EFFECT; HUMAN; KIDNEY; METABOLOMICS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; METABOLOMICS; TRIAZINES;

EID: 84901237928     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800141-7.00003-6     Document Type: Chapter

References (96)

1. Choudhury D., Ahmed Z. Drug-associated renal dysfunction and injury. Nat. Clin. Pract. Nephrol. 2006, 2:80-91.
2. Hoste E.A., Kellum J.A. Acute kidney injury: epidemiology and diagnostic criteria. Curr. Opin. Crit. Care 2006, 12:531-537.
3. Perazella M.A. Drug-induced nephropathy: an update. Expert Opin. Drug Saf. 2005, 4:689-706.
4. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 2002, 1:153-161.
5. Wishart D.S. Applications of metabolomics in drug discovery and development. Drugs R&D 2008, 9:307-322.
6. Roux A., Lison D., Junot C., Heilier J.F. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: a review. Clin. Biochem. 2011, 44:119-135.
7. Beger R.D., Sun J., Schnackenberg L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 2010, 243:154-166.
8. Zhang A., Sun H., Wang P., Han Y., Wang X. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity. Pharmazie 2012, 67:99-105.
9. Boudonck K.J., Rose D.J., Karoly E.D., et al. Metabolomics for early detection of drug-induced kidney injury: review of the current status. Bioanalysis 2009, 1:1645-1663.
10. Wishart D.S. Metabolomics in monitoring kidney transplants. Curr. Opin. Nephrol. Hypertens. 2006, 15:637-642.
11. Zhao Y.Y. Metabolomics in chronic kidney disease. Clin. Chim. Acta 2013, 422:59-69.
12. Xu E.Y., Perlina A., Vu H., et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem. Res. Toxicol. 2008, 21:1548-1561.
13. Fanos V., Antonucci R., Zaffanello M., Mussap M. Nenatal drug induced nephrotoxicity: old and next generation biomarkers for early detection and management of neonatal drug-induced nephrotoxicity, with special emphasis on uNGAL and on metabolomics. Curr. Med. Chem. 2012, 19:4595-4605.
14. Boudonck K.J., Mitchell M.W., Német L., et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 2009, 37:280-292.
15. Portilla D., Li S., Nagothu K.K., et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 2006, 69:2194-2204.
16. van de Poll M.C., Soeters P.B., Deutz N.E., Fearon K.C., Dejong C.H. Renal metabolism of amino acids: its role in interorgan amino acid exchange. Am. J. Clin. Nutr. 2004, 79:185-197.
17. Seiler N., Raul F. Polyamines and apoptosis. J. Cell. Mol. Med. 2005, 9:623-642.
18. Wallace H.M., Niiranen K. Polyamine analogues-an update. Amino Acids 2007, 33:261-265.
19. Sieber M., Hoffmann D., Adler M., et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci. 2009, 109:336-349.
20. 1H NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 2005, 10:173-187.
21. Espandiari P., Zhang J., Rosenzweig B.A., et al. The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicol. Sci. 2007, 99:637-648.
22. Ma X., Idle J.R., Krausz K.W., et al. Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. J. Pineal Res. 2006, 40:343-349.
23. Nava M., Romero F., Quiroz Y., et al. Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats. Am. J. Physiol. Renal Physiol. 2000, 279:F910-F918.
24. Sener G., Sehirli A.O., Altunbas H.Z., et al. Melatonin protects against gentamicin-induced nephrotoxicity in rats. J. Pineal Res. 2002, 32:231-236.
25. 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 2004, 129:535-541.
26. Sun J.C., Bhattacharyya S., Schnackenberg L.K., et al. Discovery of early urinary biomarkers in preclinical study of gentamicin-induced kidney injury and recovery in rats. Metabolomics 2012, 8:1181-1193.
27. Lv H., Liu L., Zhang Y., et al. Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Mol. Biosyst. 2010, 6:2056-2067.
28. Gnanasoundari M., Pari L. Impact of naringenin on oxytetracycline-mediated oxidative damage in kidney of rats. Ren. Fail. 2006, 28:599-605.
29. 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J. Pharm. Biomed. Anal. 2004, 35:599-608.
30. Saad S.Y., Najjar T.A. Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats. Arch. Toxicol. 2005, 79:493-499.
31. Padi S.S., Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron 2002, 92:685-692.
32. Klawitter J., Klawitter J., Kushner E., et al. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J. Proteome Res. 2010, 9:865-875.
33. Klawitter J., Bendrick-Peart J., Rudolph B., et al. Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem. Res. Toxicol. 2009, 22:118-128.
34. Gonwa T.A., Hricik D.E., Brinker K., Grinyo J.M., Schena F.P. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002, 74:1560-1567.
35. Serkova N.J., Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther. Drug Monit. 2005, 27:733-737.
36. Klawitter J., Klawitter J., Schmitz V., et al. Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism. J. Proteome Res. 2012, 11:5135-5144.
37. Gartland K.P., Bonner F.W., Nicholson J.K. Investigations into the biochemical effects of region-specific nephrotoxins. Mol. Pharmacol. 1989, 35:242-250.
38. Wilmes A., Limonciel A., Aschauer L., et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics 2013, 79:180-194.
39. Han S.Y., Mun K.C., Choi H.J., et al. Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells. Transplant. Proc. 2006, 38:2240-2241.
40. Huang C., Lei H., Zhao X., Tang H., Wang Y. Metabolic influence of acute cyadox exposure on Kunming mice. J. Proteome Res. 2013, 12:537-545.
41. Holmes E., Nicholson J.K., Nicholls A.W., et al. The identification of novel biomarkers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine. Chemometr. Intell. Lab. Syst. 1998, 44:245-255.
42. 1H NMR spectroscopy. J. Toxicol. Environ. Health A 2009, 72:374-384.
43. 1H NMR-based metabonomic analysis of metabolic profiling in diabetic nephropathy rats induced by streptozotocin. Am. J. Physiol. Renal Physiol. 2011, 300:F947-F956.
44. Li F., Patterson A.D., Höfer C.C., et al. Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem. Pharmacol. 2010, 80:1063-1074.
45. Wen H., Yang H., Choi M.J., et al. Identification of urinary biomarkers related to cisplatin-induced acute renal toxicity using NMR-based metabolomics. Biomol. Ther. 2011, 19:38-44.
46. Bae J.Y., Lee B.M., Han E.Y., et al. Urinary biomarkers for cisplatin-induced nephrotoxicity using metabolomic approach in vivo. Toxicol. Lett. 2011, 205S:S217.
47. Kim H.S., Kim T.H., Lee Y.J., Ahn M.Y., Kim H.S. Metabolomic profiling of cisplatin-induced nephrotoxicity in human normal kidney HK-2 cells. FASEB J. 2011, 25:1087.12.
48. Espandiari P., Rosenzweig B., Zhang J., et al. Age-related differences in susceptibility to cisplatin-induced renal toxicity. J. Appl. Toxicol. 2010, 30:172-182.
49. Santos N.A., Catão C.S., Martins N.M., et al. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch. Toxicol. 2007, 81:495-504.
50. Saad S.Y., Arafah M.M., Najjar T.A. Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats. Cancer Chemother. Pharmacol. 2007, 59:455-460.
51. Mengs U., Stotzem C.D. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch. Toxicol. 1993, 67:307-311.
52. Ni Y., Su M., Qiu Y., et al. Metabolic profiling using combined GC-MS and LC-MS provides a systems understanding of aristolochic acid-induced nephrotoxicity in rat. FEBS Lett. 2007, 581:707-711.
53. Chen M., Su M., Zhao L., et al. Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. J. Proteome Res. 2006, 5:995-1002.
54. Chan W., Cai Z. Aristolochic acid induced changes in the metabolic profile of rat urine. J. Pharm. Biomed. Anal. 2008, 46:757-762.
55. Chan W., Lee K.C., Liu N., et al. Liquid chromatography/mass spectrometry for metabonomics investigation of the biochemical effects induced by aristolochic acid in rats: the use of information-dependent acquisition for biomarker identification. Rapid Commun. Mass Spectrom. 2008, 22:873-880.
56. Lin S., Chan W., Li J., Cai Z. Liquid chromatography/mass spectrometry for investigating the biochemical effects induced by aristolochic acid in rats: the plasma metabolome. Rapid Commun. Mass Spectrom. 2010, 24:1312-1318.
57. 1H NMR. Chem. J. Chin. Univ. 2010, 31:927-932.
58. Lou Y., Li J., Lu Y., et al. Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats. Toxicol. Lett. 2011, 201:72-79.
59. Zhang X., Wu H., Liao P., et al. NMR-based metabonomic study on the subacute toxicity of aristolochic acid in rats. Food Chem. Toxicol. 2006, 44:1006-1014.
60. Tsai D.M., Kang J.J., Lee S.S., et al. Metabolomic analysis of complex Chinese remedies: examples of induced nephrotoxicity in the mouse from a series of remedies containing aristolochic acid. Evid. Based Complement Alternat. Med. 2013, 2013:263757.
61. Ma C., Bi K., Su D., et al. Serum and kidney metabolic changes of rat nephrotoxicity induced by Morning Glory Seed. Food Chem. Toxicol. 2010, 48:2988-2993.
62. Ma C., Bi K., Zhang M., et al. Metabonomic study of biochemical changes in the urine of Morning Glory Seed treated rat. J. Pharm. Biomed. Anal. 2010, 53:559-566.
63. Ma C., Bi K., Zhang M., et al. Toxicology effects of Morning Glory Seed in rat: a metabonomic method for profiling of urine metabolic changes. J. Ethnopharmacol. 2010, 130:134-142.
64. Yu Y., Ma C., Bi K., et al. A metabonomic analysis of urine from rats treated with rhizome alismatis using ultra-performance liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 25:2633-2640.
65. Wei L., Liao P., Wu H., et al. Toxicological effects of cinnabar in rats by NMR-based metabolic profiling of urine and serum. Toxicol. Appl. Pharmacol. 2008, 227:417-429.
66. 1H NMR spectroscopy. Toxicol. Appl. Pharmacol. 2009, 234:314-325.
67. 1H NMR spectroscopy. J. Ethnopharmacol. 2013, 146:572-580.
68. Bundy J.G., Spurgeon D.J., Svendsen C., et al. Environmental metabonomics: applying combination biomarker analysis in earthworms at a metal contaminated site. Ecotoxicology 2004, 13:797-806.
69. Al-Nasser I.A. Cadmium hepatotoxicity and alterations of the mitochondrial function. J. Toxicol. Clin. Toxicol. 2000, 38:407-413.
70. 1H NMR) in rats. Toxicol. Appl. Pharmacol. 2010, 249:114-126.
71. 1H NMR spectroscopy of intact tissue and pattern recognition. J. Pharm. Biomed. Anal. 2006, 40:375-381.
72. Feng J., Liu H., Bhakoo K.K., Lu L., Chen Z. A metabonomic analysis of organ specific response to USPIO administration. Biomaterials 2011, 32:6558-6569.
73. Chen Q., Zhang R., Li W.M., et al. The protective effect of grape seed procyanidin extract against cadmium-induced renal oxidative damage in mice. Environ. Toxicol. Pharmacol. 2013, 36:759-768.
74. Lei R., Wu C., Yang B., et al. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats. Toxicol. Appl. Pharmacol. 2008, 232:292-301.
75. 1H-NMR-based metabonomics. Am. J. Physiol. Renal Physiol. 2010, 298:F461-F470.
76. Xie G., Zheng X., Qi X., et al. Metabonomic evaluation of melamine-induced acute renal toxicity in rats. J. Proteome Res. 2010, 9:125-133.
77. Zheng X., Zhao A., Xie G., et al. Melamine-induced renal toxicity is mediated by the gut microbiota. Sci. Transl. Med. 2013, 5:172ra22.
78. Schnackenberg L.K., Sun J., Pence L.M., et al. Metabolomics evaluation of hydroxyproline as a potential marker of melamine and cyanuric acid nephrotoxicity in male and female Fischer F344 rats. Food Chem. Toxicol. 2012, 50:3978-3983.
79. Kim T.H., Ahn M.Y., Lim H.J., et al. Evaluation of metabolomic profiling against renal toxicity in Sprague-Dawley rats treated with melamine and cyanuric acid. Arch. Toxicol. 2012, 86:1885-1897.
80. Zgoda-Pols J.R., Chowdhury S., Wirth M., et al. Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice. Toxicol. Appl. Pharmacol. 2011, 255:48-56.
81. Ohta T., Masutomi N., Tsutsui N., et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol. Pathol. 2009, 37:521-535.
82. Williams R.E., Major H., Lock E.A., Lenz E.M., Wilson I.D. D-serine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology 2005, 207:179-190.
83. Ellis J.K., Athersuch T.J., Cavill R., et al. Metabolic response to low-level toxicant exposure in a novel renal tubule epithelial cell system. Mol. Biosyst. 2011, 7:247-257.
84. Sieber M., Wagner S., Rached E., et al. Metabonomic study of ochratoxin A toxicity in rats after repeated administration: phenotypic anchoring enhances the ability for biomarker discovery. Chem. Res. Toxicol. 2009, 22:1221-1231.
85. Zhang H., Ding L., Fang X., et al. Biological responses to perfluorododecanoic acid exposure in rat kidneys as determined by integrated proteomic and metabonomic studies. PLoS One 2011, 6:e20862.
86. Waters N.J., Waterfield C.J., Farrant R.D., Holmes E., Nicholson J.K. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem. Res. Toxicol. 2005, 18:639-654.
87. Kim C.D., Kim E.Y., Yoo H., et al. Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. Transplantation 2010, 90:748-756.
88. Klawitter J., Haschke M., Kahle C., et al. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br. J. Clin. Pharmacol. 2010, 70:241-251.
89. Wang Y., Jiang Z.T., Liang Q.L., et al. Metabonomics research of the influence of melamine to the urine metabolism of the children based on UPLC/TOF-MS. Chem. J. Chin. Univ. 2010, 31:57-60.
90. Gao H., Dong B., Liu X., et al. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta 2008, 624:269-277.
91. Tosi M.R., Rodriguez-Estrada M.T., Lercker G., et al. Magnetic resonance spectroscopy and chromatographic methods identify altered lipid composition in human renal neoplasms. Int. J. Mol. Med. 2004, 14:93-100.
92. Perroud B., Lee J., Valkova N., et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer 2006, 5:64.
93. Kind T., Tolstikov V., Fiehn O., Weiss R.H. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal. Biochem. 2007, 363:185-195.
94. Sun J., Shannon M., Ando Y., et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J. Chromatogr. B 2012, 893-894:107-113.
95. Beger R.D., Holland R.D., Sun J., et al. Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr. Nephrol. 2008, 23:977-984.
96. Wang J., Zhou Y., Xu M., et al. Urinary metabolomics in monitoring acute tubular injury of renal allografts: a preliminary report. Transplant. Proc. 2011, 43:3738-3742.